News blog
Scancell Holdings
- BY: Andrew Hore |
- POSTED: 19/12/2010 |
Vaccines developer Scancell Holdings says that recruitment for the phase I clinical trial for melanoma vaccine called SCIB1.
The SCIB1 trial commenced in June and phase I results were originally expected to be available by the middle of 2011. They are likely to be released later in 2011. The phase I/II clinical trial should still be completed before the end of 2012.
Scancell raised £2.5m at 45p a share in April. At 75.25p a share, Scancell is valued at £12m.
Matrix was appointed joint broker in September.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|